AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination therapy Breztri Aerosphere in patients with uncontrolled asthma.

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.

Breztri is an inhaled triple-combination therapy ... and asthma control at week 60. AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on ...

AstraZeneca will present full data at an upcoming meeting. Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents with ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

AstraZeneca recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma therapy, marking a milestone in improving care standards for asthma patients.

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the message that the product frees chronic obstructive pulmonary disease (COPD) patients to leave their bad ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri ...